Scholarlink

Purpose <p>The study deals with eHTA of new technology for STEMI patients indicated for PCI treatment, which contains diagnostic of rVF risks and medication to prevent rVF in at-risk patients above standard approved procedure. Due to the recommended medication procedure for STEMI patients with identified high rVF risks during PCI and its effectiveness have not been established the goal is to find out what level of medication effectiveness which will be sufficient for the cost-effectiveness of the new technology.</p> Methods <p>Scenarios where the effectiveness of rVF protecting medication administered to predisposed STEMI patients undergoing PCI varies from 5 to 95% were analyzed. Cost-effectiveness was evaluated by the CEA.</p> Results <p>The determined minimum effectiveness of rVF protecting medication to achieve the technology and procedure cost-effectiveness is 7.54%. Even if medication efficacy is at least 39.58%, the technology is “dominant” and the ICER is in the South-east [SE] quadrant.</p> Conclusions <p>Cost-effectiveness analysis show that for all scenarios modeled, except the 5% medication effectiveness scenario, the technology appears to be cost-effective. so such new technology will probably be very attractive for investors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early health technology assessment of diagnostic cardiology technology for reperfusion VF prediction of STEMI patients indicated for PCI

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月6日

查看全文
  • Marija Gorelova,
  • Gleb Donin,
  • Peter Kneppo

摘要

Purpose

The study deals with eHTA of new technology for STEMI patients indicated for PCI treatment, which contains diagnostic of rVF risks and medication to prevent rVF in at-risk patients above standard approved procedure. Due to the recommended medication procedure for STEMI patients with identified high rVF risks during PCI and its effectiveness have not been established the goal is to find out what level of medication effectiveness which will be sufficient for the cost-effectiveness of the new technology.

Methods

Scenarios where the effectiveness of rVF protecting medication administered to predisposed STEMI patients undergoing PCI varies from 5 to 95% were analyzed. Cost-effectiveness was evaluated by the CEA.

Results

The determined minimum effectiveness of rVF protecting medication to achieve the technology and procedure cost-effectiveness is 7.54%. Even if medication efficacy is at least 39.58%, the technology is “dominant” and the ICER is in the South-east [SE] quadrant.

Conclusions

Cost-effectiveness analysis show that for all scenarios modeled, except the 5% medication effectiveness scenario, the technology appears to be cost-effective. so such new technology will probably be very attractive for investors.